CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia

NCT04154709 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: CTA101

Sponsor

Kai Lin Xu; Jun Nian Zheng

Collaborators

[object Object]